2d83a9e6-da2d-47e1-b2e7-4b07b108f7bd
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.620
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.560
- MYC_TARGETS_V1+0.510
- MYC_TARGETS_V2+0.490
- FATTY_ACID_METABOLISM+0.410
- DNA_REPAIR+0.400
- GLYCOLYSIS+0.320
- ADIPOGENESIS+0.310
- PEROXISOME+0.310
- CHOLESTEROL_HOMEOSTASIS+0.290
Top 10 suppressed
- ANGIOGENESIS-0.490
- HEDGEHOG_SIGNALING-0.490
- UV_RESPONSE_DN-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- MITOTIC_SPINDLE-0.350
- WNT_BETA_CATENIN_SIGNALING-0.320
- KRAS_SIGNALING_UP-0.260
- ALLOGRAFT_REJECTION-0.220
- MYOGENESIS-0.220
- APICAL_JUNCTION-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.886 |
| 2 | SRR8518248 | — | E | 0.880 |
| 3 | 6f2c5313-1c83-46c7-a15c-5b9526c1763b | — | — | 0.876 |
| 4 | 8c76ce45-f110-4f6a-b413-13a1a1aeddef | — | — | 0.871 |
| 5 | 054d5602-4089-4f34-a667-14c8edbb4167 | — | — | 0.871 |
| 6 | dfb9c45f-cb52-4e36-b663-1a9e8c7c0b47 | — | — | 0.862 |
| 7 | TCGA-37-4133-01A-01R-1100-07 | — | cohortSQ1 | 0.861 |
| 8 | b2b4cc41-5760-4463-bcde-16115ceb12c2 | — | — | 0.860 |
| 9 | 79a36f11-38bb-42ed-a95a-ae2a9eea0f6a | — | — | 0.857 |
| 10 | ee24b470-4509-4687-a91e-6d2b967336b9 | — | — | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.620 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.410 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.310 | Inavolisib | — uncovered |
| PEROXISOME | 0.310 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.280 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |